Sundia Investment Group

Sundia MediTech is a premier contract research organization (CRO) providing integrated drug discovery and development services to the global pharmaceutical and biotechnology industries. Established in 2004 and headquartered in Shanghai, China, the company offers a broad suite of services including medicinal chemistry, lead optimization, custom synthesis, and process chemistry. Sundia also provides biology, pharmacology, and DMPK services to support the transition from early-stage research to clinical development. In 2020, Sundia was acquired by Bellen Chemistry, a leading provider of chemical synthesis services, to create a more comprehensive integrated service platform. The combined entity offers end-to-end solutions from discovery through to commercial manufacturing, helping clients accelerate their drug development timelines.